Antipsychotic with (sub-) nanomolar affinity for dopamine and α-adrenergic receptors (Ki of 0.4 nM, 1.5 nM, 1.5 nM, 3.2 nM, 2.4 nM for D2, D3, D4, α1A, and α1B resp.).
Recently, Thioridazine was found to inhibit full length recombinant MALT1 (IC50 3.43 μM). It inhibits anti-apoptotic NF-κB signaling and elicits toxic effects selectively on MALT1-dependent ABC-DLBCL cells. Additionally, it suppresses tumor growth activity by targeting the PI3K/Akt/mTOR/p70S6K signaling pathway.